Expert disagreements, alternative perspectives, and minority opinions.
“Some researchers argue that GIPR antagonism, rather than agonism, is the more effective pathway for weight loss. GIPR-deficient mice are resistant to obesity, and tirzepatide's imbalanced bias may actually result in functional receptor desensitisation that mimics antagonism.”
Editorial Context
While tirzepatide is designed as a GIP agonist, the debate over whether its benefit comes from activating or effectively silencing the GIP receptor remains unresolved.
“A patient who loses significant muscle mass on the drug and then regains weight as almost entirely fat after stopping could end up in a worse metabolic state than before treatment, with a permanently lowered basal metabolic rate due to muscle loss.”
Editorial Context
The standard 25% lean mass loss figure from controlled trials may understate the real-world problem, where absolute lean mass losses appear higher than with semaglutide.
“Critical health scholars argue these medications medicalise body size and reinforce weight stigma. Focusing on pharmaceutical fixes for a population-level issue ignores the social determinants of health like food deserts and sedentary environments.”
Editorial Context
The counterargument focuses on the long-term dependency implications and high cost, questioning whether billions spent on individual treatment would be more effective as systemic food policy reform.
“Some patients report a blunting of pleasures beyond food: hobbies, social interaction, and sexual interest. This suggests the drug may broadly dampen reward signalling rather than selectively targeting caloric intake.”
Editorial Context
While reducing food noise is a clinical benefit, the broader dopaminergic impact on the mesolimbic reward system raises questions about quality of life on long-term therapy.
“Public health economists question whether the billions spent by health systems on individual treatments would be more effectively spent on systemic food policy reform, school lunch programmes, or urban infrastructure to encourage movement.”
Editorial Context
This is not a claim that the drug does not work, but a resource allocation argument: whether per-patient pharmaceutical spending addresses the population-level problem.